Active
Mainboard

Rubicon Research Ltd

Rubicon Research Ltd IPO opened on 09 Oct 2025 and closed on 13 Oct 2025, with a price band of ₹461–₹485 per share. The IPO had a lot size of 30 shares, requiring a minimum investment of ₹14,550 per lot at the upper price band. The issue size was ₹1377.5 crore, and the shares get listed on 16 Oct 2025.

Rubicon Research Ltd IPO Details

Listing Date

16 Oct 2025

Bid Price

₹461 - ₹485

Lot Size

30 Shares

Minimum Investment

₹14,550 / Lot

Issue Size

₹1377.5 Cr

Employee Discount

₹46 per share

Key Dates to Track

    Here are the important dates you need to know in order to participate in this IPO

tick

Offer Start Date

9th Oct

tick

Offer End Date

13th Oct

tick

Allotment Date

14th Oct

tick

Refund Initiation

15th Oct

tick

Demat Transfer

15th Oct

tick

Listing Date

16th Oct

About Rubicon Research Ltd IPO

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company focused on the development, manufacturing, and commercialisation of differentiated formulations. As of June 30, 2025, the company holds approvals for 72 products under the US FDA’s ANDA and NDA framework, with 66 products currently commercialised. Its presence in the US generic pharmaceutical market, valued at USD 2,455.7 million, generated revenue of USD 195 million for Rubicon in Fiscal 2024. The company has an additional 17 products awaiting US FDA approval and 63 products in various stages of development, reflecting a consistent pipeline for future growth.
 

Rubicon Research also markets over 350 SKUs to 96 customers, including major wholesalers covering more than 90% of wholesale drug distribution in the US. The company extends its operations internationally with 48 product applications across Australia, the UK, Singapore, Saudi Arabia, and the UAE. Its services include contract manufacturing for select customers in India, Australia, and New Zealand. Rubicon operates three manufacturing facilities in India and maintains two US FDA inspected R&D centres in India and Canada, supporting both domestic and international product development.

Rubicon Research Ltd Shareholding Pattern

  Pre-Issue Post-Issue
Promoter Group 77.34% 61.79%
Public Group 22.66% 38.21%

Rubicon Research Ltd IPO Reservation

QIB Shares Offered 85,09,788 (29.96%)
NII (HNI) Shares Offered 42,54,894 (14.98%)
Retail Shares Offered 28,36,596 (9.99%)
Anchor Investor Shares Offered 1,27,64,681 (44.94%)
Total Shares Offered 2,84,02,040
Total Shares With Anchor Investor 2,84,02,040

Rubicon Research Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 30 ₹14,550
Retail (Max) 13 390 ₹1,89,150
S HNI (Min) 14 420 ₹2,03,700
S HNI (Max) 68 2,040 ₹9,89,400
B HNI (MIN) 69 2,070 ₹10,03,950

Rubicon Research Ltd IPO Anchor Portion Size

Bid Date October 08, 2025

Rubicon Research Ltd IPO registrar

MUFG Intime India Pvt Ltd
Phone Number +91 81081 14949
Email Id rubicon.ipo @linkintime.co.in
Website https://in.mpms.mufg.com

Rubicon Research Ltd IPO Lead Manager

1. Axis Capital Ltd

2. IIFL Securities Ltd

3. JM Financial Ltd

4. SBI Capital Markets Ltd

Rubicon Research Ltd Financial Information

March 31, 2025 March 31, 2024 March 31, 2023
Net Worth ₹540.98 Cr ₹385 Cr ₹286.38 Cr
Reserves and Surplus ₹525.57 Cr ₹369.79 Cr ₹281.3 Cr
Total Borrowing ₹393.17 Cr ₹396.41 Cr ₹317.91 Cr

Strength of Rubicon Research Ltd

  • We are the fastest growing Indian pharmaceutical company amongst our peers and the only Indian company focused completely on the US market.
  • Our data-driven product selection framework has allowed us to build a product portfolio with a combination of new and specialty products allowing us to withstand pricing pressures.
  • Our R&D capabilities and continuing investment allow us to pursue complex products that offer strong revenue opportunities.
  • Robust sales and distribution capabilities in the US.
  • Strong track record of compliance combined with expertise in cost effective manufacturing
  • Experienced and entrepreneurial management team with a proven track record and marquee private equity investor.

Risks Involved

  • We derive Rs.3,507.36 million and 99.50%, and Rs.12,649.23 million and 98.49%, respectively, of our revenue from operations from the United States for the three month period ended June 30, 2025 and Fiscal 2025, respectively, and any adverse developments in the United States such as imposition of tariffs could have an adverse effect on our business and results of operations.
  • As the manufacture of our products is technically complex and highly regulated, product recalls, regulatory inspection failures or shortcomings at our manufacturing facilities or other problems may reduce sales, adversely affect our business, financial condition and results of operations and delay the launch of new products, and in some cases may lead to closures of our facilities.
  • We have a history of net losses, negative earnings per share ("EPS") and return on capital employed. We need to generate and sustain increased revenues while managing our expenses to achieve profitability, and our inability to achieve these goals may have an adverse effect on our business, results of operations, cash flows and financial condition.
  • In Fiscals 2025, 2024 and 2023, and the three month period ended June 30, 2025 and 2024 we derived 71.22%, 65.14% and 62.99%, and 77.04% and 70.46%, respectively, of our revenue from sale of goods from our top five customers and the loss of one or more such customers could adversely affect our business and prospects.
  • Our operations are subject to high working capital and capital expenditure requirements, and our inability to maintain an optimal level of working capital or financing required may impact our operations adversely.
  • Any disruption, breakdown or shutdown of our research and development and manufacturing facilities may have a material adverse effect on our business, financial condition, results of operations and cash flows.
  • Our Company is involved in certain legal proceedings. Any adverse decision in such proceedings may render us/them liable to liabilities/penalties and may adversely affect our business, financial condition, results of operations and cash flows.
  • Our success depends on our ability to execute our growth strategies. If we are unable to sustain or manage our growth, our business, results of operations, cash flows and financial condition may be adversely affected.
  • We face significant competitive pressures in our business from other pharmaceutical manufacturers. Our inability to compete effectively would be detrimental to our business and prospects for future growth.
  • The market in which we operate is subject to consolidation and disruption, and our inability to navigate such changes could adversely affect our business, financial condition and results of operation.
stock

Invest in IPOs with ease

Sign-in to invest with your demat account, or set up a new demat account for free

Industry Outlook of Rubicon Research IPO

  • Indian pharmaceutical formulations sector appears to be growing steadily, especially in regulated markets such as the United States and Europe.

  • Demand in the US generics and specialty products market is under pressure from regulatory complexity, cost of raw materials, and competition from other Asian players.

  • R&D investment is increasing among pharma firms, with more companies seeking ANDA and NDA approvals, drug-device combinations and complex dosage forms.

  • Regulatory requirements (US FDA, WHO-GMP, Health Canada etc.) are shaping manufacturing and compliance costs. Firms with accredited facilities may have smoother paths to market.

  • Global health-crises, supply chain disruptions, and raw material sourcing from China are creating both risks and opportunities for Indian exporters.

  • Domestic growth (India) and demand from Europe may help offset slowing growth in the US market.

  • Firms that maintain a deep product pipeline, ensure high commercialization rates of approved products, and expand manufacturing capacity may have more consistent revenue upside.

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Rubicon Research IPO.  

Explore Other IPOs

  • Current IPOs
  • Upcoming IPOs
  • Closed IPOs
  • IPO Performance
  • All
  • MainBoard
  • SME
  • All
  • MainBoard
  • SME
Mehul Telecom Limited IPO
Bidding Period
17th Apr 2026 - 4th Apr 2026
Price Range
₹96.0 - 98.0
IPO Size
₹27,73,00,000
Aarvee Engineering Consultants Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aastha Spintex Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Absolute Project India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AceVector Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Adroit Industries India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanced SysTek Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanta Enterprises Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advit Jewels Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aggcon Equipments International Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Agilus Diagnostics Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Airox Technologies Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ajay Poly Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alcobrew Distilleries India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allchem Lifescience Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allied Engineering Works Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alpine Texworld Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Annu Projects Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AOne Steels India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
APPL Containers Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
NO ACTIVE IPO HERE
  • All
  • MainBoard
  • SME
OM POWER TRANSMISSION LIMITED IPO
Bidding Period
9th Apr 2026 - 4th Apr 2026
Price Range
₹166.0 - 175.0
IPO Size
₹1,50,00,00,000
EMIAC TECHNOLOGIES LIMITED IPO
Bidding Period
27th Mar 2026 - 4th Apr 2026
Price Range
₹93.0 - 98.0
IPO Size
₹32,00,00,000
SAFETY CONTROLS AND DEVICES LIMITED IPO
Bidding Period
6th Apr 2026 - 4th Apr 2026
Price Range
₹75.0 - 80.0
IPO Size
₹48,00,00,000
VIVID ELECTROMECH LIMITED IPO
Bidding Period
25th Mar 2026 - 3rd Mar 2026
Price Range
₹528.0 - 555.0
IPO Size
₹1,31,00,00,000
SAI PARENTERAL'S LIMITED IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹372.0 - 392.0
IPO Size
₹4,09,00,00,000
AMIR CHAND JAGDISH KUMAR EXPORTS LIMITED IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹201.0 - 212.0
IPO Size
₹4,40,00,00,000
HIGHNESS MICROELECTRONICS LIMITED IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹114.0 - 120.0
IPO Size
₹22,00,00,000
POWERICA LIMITED IPO
Bidding Period
24th Mar 2026 - 3rd Mar 2026
Price Range
₹375.0 - 395.0
IPO Size
₹11,00,00,00,000
TIPCO ENGINEERING INDIA LIMITED IPO
Bidding Period
23rd Mar 2026 - 3rd Mar 2026
Price Range
₹84.0 - 89.0
IPO Size
₹61,00,00,000
SPECIALITY MEDICINES LIMITED IPO
Bidding Period
20th Mar 2026 - 3rd Mar 2026
Price Range
₹117.0 - 124.0
IPO Size
₹29,00,00,000
CENTRAL MINE PLANNING AND DESIGN INSTITUTE LIMITED IPO
Bidding Period
20th Mar 2026 - 3rd Mar 2026
Price Range
₹163.0 - 172.0
IPO Size
₹18,42,00,00,000
NOVUS LOYALTY LIMITED IPO
Bidding Period
17th Mar 2026 - 3rd Mar 2026
Price Range
₹139.0 - 146.0
IPO Size
₹60,00,00,000
GSP CROP SCIENCE LIMITED IPO
Bidding Period
16th Mar 2026 - 3rd Mar 2026
Price Range
₹304.0 - 320.0
IPO Size
₹4,00,00,00,000
INNOVISION LIMITED IPO
Bidding Period
10th Mar 2026 - 3rd Mar 2026
Price Range
₹494.0 - 519.0
IPO Size
₹3,06,00,00,000
RAAJMARG INFRA INVESTMENT TRUST IPO
Bidding Period
11th Mar 2026 - 3rd Mar 2026
Price Range
₹99.0 - 100.0
IPO Size
₹60,00,00,00,000
APSIS AEROCOM LIMITED IPO
Bidding Period
11th Mar 2026 - 3rd Mar 2026
Price Range
₹104.0 - 110.0
IPO Size
₹36,00,00,000
RAJPUTANA STAINLESS LIMITED IPO
Bidding Period
9th Mar 2026 - 3rd Mar 2026
Price Range
₹116.0 - 122.0
IPO Size
₹2,55,00,00,000
SRINIBAS PRADHAN CONSTRUCTIONS LIMITED IPO
Bidding Period
6th Mar 2026 - 3rd Mar 2026
Price Range
₹91.0 - 98.0
IPO Size
₹20,00,00,000
ELFIN AGRO INDIA LIMITED IPO
Bidding Period
5th Mar 2026 - 3rd Mar 2026
Price Range
₹47.0 - 47.0
IPO Size
₹25,00,00,000
SEDEMAC MECHATRONICS LIMITED IPO
Bidding Period
4th Mar 2026 - 3rd Mar 2026
Price Range
₹1287.0 - 1352.0
IPO Size
₹10,87,00,00,000
  • All
  • MainBoard
  • SME
GSP CROP SCIENCE LIMITED IPO
Issue Prize
320.00
Listing Day Close
356.10(11.25%)
INNOVISION LIMITED IPO
Issue Prize
519.00
Listing Day Close
372.80(-28.13%)
RAAJMARG INFRA INVESTMENT TRUST IPO
Issue Prize
100.00
Listing Day Close
106.83(7.00%)
APSIS AEROCOM LIMITED IPO
Issue Prize
110.00
Listing Day Close
160.65(46.36%)
RAJPUTANA STAINLESS LIMITED IPO
Issue Prize
122.00
Listing Day Close
112.90(-7.38%)
SRINIBAS PRADHAN CONSTRUCTIONS LIMITED IPO
Issue Prize
98.00
Listing Day Close
104.40(6.12%)
ELFIN AGRO INDIA LIMITED IPO
Issue Prize
47.00
Listing Day Close
47.60(2.13%)
SEDEMAC MECHATRONICS LIMITED IPO
Issue Prize
1352.00
Listing Day Close
1452.10(7.40%)
ACETECH ECOMMERCE LIMITED IPO
Issue Prize
112.00
Listing Day Close
117.60(5.36%)
STRIDERS IMPEX LIMITED IPO
Issue Prize
72.00
Listing Day Close
66.50(-6.94%)
OMNITECH ENGINEERING LIMITED IPO
Issue Prize
227.00
Listing Day Close
205.15(-9.69%)
YAAP DIGITAL LIMITED IPO
Issue Prize
145.00
Listing Day Close
133.35(-8.28%)
PNGS REVA DIAMOND JEWELLERY LIMITED IPO
Issue Prize
386.00
Listing Day Close
413.95(7.25%)
CLEAN MAX ENVIRO ENERGY SOLUTIONS LIMITED IPO
Issue Prize
1053.00
Listing Day Close
867.90(-17.57%)
SHREE RAM TWISTEX LIMITED IPO
Issue Prize
104.00
Listing Day Close
73.45(-29.81%)
MOBILISE APP LAB LIMITED IPO
Issue Prize
80.00
Listing Day Close
67.30(-16.25%)
KIAASA RETAIL LIMITED IPO
Issue Prize
127.00
Listing Day Close
116.85(-7.87%)
ACCORD TRANSFORMER AND SWITCHGEAR LIMITED IPO
Issue Prize
46.00
Listing Day Close
52.50(15.22%)
GAUDIUM IVF AND WOMEN HEALTH LIMITED IPO
Issue Prize
79.00
Listing Day Close
80.48(1.27%)
MANILAM INDUSTRIES INDIA LIMITED IPO
Issue Prize
69.00
Listing Day Close
52.45(-24.64%)

Frequently Asked Questions

What is Rubicon Research Ltd IPO?

Answer Field

Rubicon Research Ltd IPO is a Mainboard IPO of 2,84,02,040 equity shares of a face value of ₹1 aggregating up to ₹1377.5 Crores. The issue is priced at ₹461 to ₹485 per share. The minimum order quantity is 30 Shares. The IPO opens on October 09, 2025, and closes on October 13, 2025. MUFG Intime India Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Rubicon Research Ltd IPO will open?

Answer Field

The Rubicon Research Ltd IPO opens on October 09, 2025 and closes on October 13, 2025.

What is the lot size of Rubicon Research Ltd?

Answer Field

Rubicon Research Ltd lot size is 30 shares, and the minimum amount required is ₹14,550.

How to apply for Rubicon Research Ltd IPO?

Answer Field

You can apply in Rubicon Research Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Rubicon Research Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Rubicon Research Ltd IPO will be done on October 14, 2025, and the allotted shares will be credited to your demat account by October 15, 2025.

When is Rubicon Research Ltd IPO listing date?

Answer Field

The Rubicon Research Ltd listing date is October 16, 2025.

Who is the registrar of Rubicon Research Ltd IPO?

Answer Field

The registrar of Rubicon Research Ltd IPO is MUFG Intime India Pvt Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

Axis Capital Ltd,IIFL Securities Ltd,JM Financial Ltd,SBI Capital Markets Ltd will be the book-running lead manager of this IPO.

What is the fresh issue of Rubicon Research Ltd IPO?

Answer Field

The fresh issue size is ₹500 Crores equity shares.

What minimum lot size can retail subscribers subscribe to Rubicon Research Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 30 shares and ₹14,550 amount.

How can I approve the UPI mandate request for Rubicon Research Ltd IPO?

Answer Field

To apply for Rubicon Research Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Rubicon Research Ltd?

Answer Field

The price of each Rubicon Research Ltd share will be ranging in between ₹461 to ₹485 per share.

What is the cut-off time for the UPI mandate for Rubicon Research Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, October 13, 2025.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|